New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 4

Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

, , ,

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

Video content above is prompted by the following:

  • Please discuss the data for 2L treatment with CAR T-cell therapy for patients who are transplant-ineligible.
    • Do the defining characteristics of transplant-ineligible used in the following studies reflect which patients are considered transplant-ineligible in the real world?
    • ALYCANTE- Phase 2 trial.
    • PILOT – Phase 2 trial.
    • What are some key takeaways from the results of these two studies?